藥明康德AH股齊大漲,Q4單季營收創新高+擬10億元回購股份
藥明康德A股盤初一度漲超8%,報69.16元;H股一度漲近11%,報72.5元,創2024年1月以來新高。消息面上,藥明康德昨晚公佈的業績顯示,不僅全年營收實現環比三連增,第四季度收入更是增至115.4億元,強勢突破22年第四季度創下的單季度營收峯值。還值得注意的是,藥明康德TIDES業務板塊2024年營收同比增長70.1%至58億元,大幅超越此前所給出的全年60%的增速指引。藥明康德還預計TIDES業務今年增長60%以上,訂單增長速度將超過收入增長速度。另外,藥明康德公告,公司擬以10億元資金回購股份,回購價格不超過人民幣92.05元/股(含)。本次回購的股份將用於註銷並減少公司註冊資本,資金來源爲公司自有資金及自籌資金。回購期限自股東大會批準方案之日起不超過12個月。(格隆匯)


Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.